Clinical Study| Volume 16, ISSUE 12, P1595-1598, December 2009

Download started.


Survival analysis of 205 patients with glioblastoma multiforme: Clinical characteristics, treatment and prognosis in China


      To study the clinical characteristics, treatment and prognosis of patients with glioblastoma multiforme (GBM) in China, we retrospectively analyzed 205 Chinese patients with histologically proven GBM. A univariate analysis of prognosis factors for survival time was performed and significant factors were tested in a multivariate analysis using the Cox regression method. Median overall survival time was 12.0 months (95% confidence interval [CI] 11.0–13.1 months). Survival rates after diagnosis were 82% at 6 months, 52% at 12 months, 27% at 18 months and 17% at 24 months. Age, preoperative Karnofsky’s performance status score and tumour location were independent preoperative predictors of prognosis and among the treatment methods of GBM, radiotherapy was the strongest predictor of prognosis followed by radical surgery and chemotherapy. The median survival time post diagnosis for Chinese patients is comparable to the 11.0–15.9 month range observed in western patients. The data suggest a lack of ethnic differences in GBM prognosis of Chinese and western patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • DeAngelis L.M.
        Brain tumors.
        N Engl J Med. 2001; 344: 114-123
        • Stark A.M.
        • Nabavi A.
        • Mehdorn H.M.
        • et al.
        Glioblastoma multiforme: report of 267 cases treated at a single institution.
        Surg Neurol. 2005; 63: 162-169
        • Bussiere M.
        • Hopman W.
        • Day A.
        • et al.
        Indicators of functional status for primary malignant brain tumor patients.
        Can J Neurol Sci. 2005; 32: 50-56
        • Stylli S.S.
        • Kaye A.H.
        • MacGregor L.
        • et al.
        Photodynamic therapy of high grade glioma - long term survival.
        J Clin Neurosci. 2005; 12: 389-398
        • Keles G.E.
        • Anderson B.
        • Berger M.S.
        The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.
        Surg Neurol. 1999; 52: 371-379
        • Lacroix M.
        • Abi-Said D.
        • Fourney D.R.
        • et al.
        A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection and survival.
        J Neurosurg. 2001; 95: 190-198
        • Mineo J.F.
        • Quintin-Roue I.
        • Lucas B.
        • et al.
        Glioblastomas: clinical study and prognosis factors.
        Neurochirurgie. 2002; 48: 500-509
        • Rainov N.G.
        • Dobberstein K.U.
        • Bahn H.
        • et al.
        Prognosis factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival.
        J Neurooncol. 1997; 35: 13-28
        • Shinoda J.
        • Sakai N.
        • Murase S.
        • et al.
        Selection of eligible patients with supratentorial glioblastoma for gross total resection.
        J Neurooncol. 2001; 52: 161-171
        • Stummer W.
        • Novotny A.
        • Stepp H.
        • et al.
        Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid induced porphyrins: a prospective study of 52 consecutive patients.
        J Neurosurg. 2000; 93: 1003-1013
        • Mineo J.F.
        • Bordron A.
        • Baroncini M.
        • et al.
        Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
        Acta Neurochir (Wien). 2007; 149: 245-253
        • Polin R.S.
        • Marko N.F.
        • Ammerman M.D.
        • et al.
        Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres.
        J Neurosurg. 2005; 102: 276-283
        • Tseng J.H.
        • Merchant E.
        • Tseng M.Y.
        Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales.
        Surg Neurol. 2006; 66: 258-263
        • Harsh G.R.
        • Levin V.A.
        • Gutin P.H.
        • et al.
        Reoperation for recurrent glioblastoma and anaplastic astrocytoma.
        Neurosurgery. 1987; 21: 615-621
        • Young B.
        • Oldfield E.H.
        • Markesbery W.R.
        • et al.
        Reoperation for glioblastoma.
        J Neurosurg. 1981; 55: 917-921
      1. Medical Research Council Brain Tumors Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 2001;19:509–518.

        • Stupp R.
        • Mason W.P.
        • van den Bent M.J.
        • et al.
        Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
        N Engl J Med. 2005; 352: 987-996
        • Barnholtz-Sloan J.
        • Maldonado J.L.
        • Williams V.L.
        • et al.
        Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.
        J Neurooncol. 2007; 85: 171-180
        • Das A.
        • Tan W.L.
        • Teo J.
        • et al.
        Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
        J Neurooncol. 2002; 60: 117-125
        • Xie D.
        • Zeng Y.X.
        • Wang H.J.
        • et al.
        Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient’s age but not with tumor’s clinicopathological pathway.
        Acta Neuropathol. 2005; 110: 481-489